---
title: "Amylyx Presents Avexitide Results; MiniMed Launches Tubeless Insulin Pump"
id: "endocrine-news-0-pharma-friday-november-21-2026"
canonical_url: "https://medichelpline.com/clinical-feed/endocrine-news-0-pharma-friday-november-21-2026"
content_type: "clinical_feed_article"
specialty: "Endocrinology"
source_name: "Endocrine News"
source_url: "https://endocrinenews.endocrine.org/pharma-friday-november-21-2026/"
published_at: "2026-11-20T19:31:50.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Amylyx Presents Avexitide Results; MiniMed Launches Tubeless Insulin Pump
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/endocrine-news-0-pharma-friday-november-21-2026
- **Specialty:** [Endocrinology](https://medichelpline.com/clinical-feed/endocrinology.md)
- **Primary Source:** Endocrine News
- **Source URL:** [Original Journal Publication](https://endocrinenews.endocrine.org/pharma-friday-november-21-2026/)
- **Published At:** 2026-11-20T19:31:50.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Amylyx Pharmaceuticals revealed Phase 3 LUCIDITY trial results for avexitide, a first-in-class GLP-1 receptor antagonist, showing a 55% reduction in hypoglycemic events in post-bariatric patients. - MiniMed received FDA clearance for MiniMed Fit™, a tubeless insulin pump with a up to seven days of wear and SmartGuard™ technology aimed at improving diabetes management. - PolarityBio announced FDA acceptance of BLA for SkinTE® for diabetic foot ulcers with a target action date of March 16, 2027, under Priority Review.
## Clinical Analysis & Structured Key Points
[Skip to content](https://endocrinenews.endocrine.org/pharma-friday-november-21-2026/#wp--skip-link--target) [Endocrine News](https://endocrinenews.endocrine.org) [![Endocrine News](https://endocrinenews.endocrine.org/wp-content/uploads/es-reversed.svg)](https://endocrinenews.endocrine.org/) * [Topics](https://endocrinenews.endocrine.org/category/health-topic/diabetes/) * [Diabetes](https://endocrinenews.endocrine.org/category/health-topic/diabetes/) * [Obesity](https://endocrinenews.endocrine.org/category/health-topic/obesity/) * [Adrenal](https://endocrinenews.endocrine.org/category/health-topic/adrenal/) * [Bone and Mineral](https://endocrinenews.endocrine.org/category/health-topic/bone-and-mineral/) * [Cardiometabolic](https://endocrinenews.endocrine.org/category/health-topic/cardiometabolic/) * [Endocrine Disruptors](https://endocrinenews.endocrine.org/category/health-topic/endocrine-disruptors/) * [Head Glands](https://endocrinenews.endocrine.org/category/health-topic/head-glands/) * [Kidney Issues](https://endocrinenews.endocrine.org/category/health-topic/kidney-issues/) * [Neoplasia and Cancer](https://endocrinenews.endocrine.org/category/health-topic/neoplasia-and-cancer/) * [Pancreas](https://endocrinenews.endocrine.org/category/health-topic/pancreas/) * [Reproductive Issues](https://endocrinenews.endocrine.org/category/health-topic/reproductive-issues/) * [Thyroid](https://endocrinenews.endocrine.org/category/health-topic/thyroid/) * [Pediatric Health](https://endocrinenews.endocrine.org/category/patient-populations/pediatric-health/) * [Men’s Health](https://endocrinenews.endocrine.org/category/patient-populations/mens-health/) * [Women’s Health](https://endocrinenews.endocrine.org/category/patient-populations/womens-health/) * [Why Endocrinology?](https://endocrinenews.endocrine.org/category/why-endocrinology/) * [Practice](https://endocrinenews.endocrine.org/category/practice/) * [Your Practice](https://endocrinenews.endocrine.org/category/practice/your-practice/) * [Your Patients](https://endocrinenews.endocrine.org/category/practice/your-patients/) * [Product / Technology](https://endocrinenews.endocrine.org/category/practice/product-technology/) * [Endocrinology Workforce](https://endocrinenews.endocrine.org/category/endocrinology-workforce/) * [Lab Notes](https://endocrinenews.endocrine.org/category/lab-notes/) * [Q&A](https://endocrinenews.endocrine.org/category/lab-notes/q-a/) * [Your Laboratory](https://endocrinenews.endocrine.org/category/your-laboratory/) * [Products and Technological Advancements in Endocrinology](https://endocrinenews.endocrine.org/category/lab-notes/products-technology/) * [Advocacy](https://endocrinenews.endocrine.org/category/advocacy/) * [Clinical](https://endocrinenews.endocrine.org/category/advocacy/clinical/) * [Research](https://endocrinenews.endocrine.org/category/advocacy/research/) * [InTouch](https://endocrinenews.endocrine.org/intouch/) * [Member News](https://endocrinenews.endocrine.org/category/in-touch/member-news-in-touch/) * [Society News](https://endocrinenews.endocrine.org/category/in-touch/society-news/) * [Podcast](https://www.endocrine.org/podcast) * [Current Issue Download](https://endocrinenews.endocrine.org/magazine/current-issue/) * [My Profile](https://ams.endocrine.org/eweb/) * [Log In](https://endocrinenews.endocrine.org/auth/login) * [Log Out](https://endocrinenews.endocrine.org/auth/logout) * [Topics](https://endocrinenews.endocrine.org/category/health-topic/diabetes/) * [Diabetes](https://endocrinenews.endocrine.org/category/health-topic/diabetes/) * [Obesity](https://endocrinenews.endocrine.org/category/health-topic/obesity/) * [Adrenal](https://endocrinenews.endocrine.org/category/health-topic/adrenal/) * [Bone and Mineral](https://endocrinenews.endocrine.org/category/health-topic/bone-and-mineral/) * [Cardiometabolic](https://endocrinenews.endocrine.org/category/health-topic/cardiometabolic/) * [Endocrine Disruptors](https://endocrinenews.endocrine.org/category/health-topic/endocrine-disruptors/) * [Head Glands](https://endocrinenews.endocrine.org/category/health-topic/head-glands/) * [Kidney Issues](https://endocrinenews.endocrine.org/category/health-topic/kidney-issues/) * [Neoplasia and Cancer](https://endocrinenews.endocrine.org/category/health-topic/neoplasia-and-cancer/) * [Pancreas](https://endocrinenews.endocrine.org/category/health-topic/pancreas/) * [Reproductive Issues](https://endocrinenews.endocrine.org/category/health-topic/reproductive-issues/) * [Thyroid](https://endocrinenews.endocrine.org/category/health-topic/thyroid/) * [Pediatric Health](https://endocrinenews.endocrine.org/category/patient-populations/pediatric-health/) * [Men’s Health](https://endocrinenews.endocrine.org/category/patient-populations/mens-health/) * [Women’s Health](https://endocrinenews.endocrine.org/category/patient-populations/womens-health/) * [Why Endocrinology?](https://endocrinenews.endocrine.org/category/why-endocrinology/) * [Practice](https://endocrinenews.endocrine.org/category/practice/) * [Your Practice](https://endocrinenews.endocrine.org/category/practice/your-practice/) * [Your Patients](https://endocrinenews.endocrine.org/category/practice/your-patients/) * [Product / Technology](https://endocrinenews.endocrine.org/category/practice/product-technology/) * [Endocrinology Workforce](https://endocrinenews.endocrine.org/category/endocrinology-workforce/) * [Lab Notes](https://endocrinenews.endocrine.org/category/lab-notes/) * [Q&A](https://endocrinenews.endocrine.org/category/lab-notes/q-a/) * [Your Laboratory](https://endocrinenews.endocrine.org/category/your-laboratory/) * [Products and Technological Advancements in Endocrinology](https://endocrinenews.endocrine.org/category/lab-notes/products-technology/) * [Advocacy](https://endocrinenews.endocrine.org/category/advocacy/) * [Clinical](https://endocrinenews.endocrine.org/category/advocacy/clinical/) * [Research](https://endocrinenews.endocrine.org/category/advocacy/research/) * [InTouch](https://endocrinenews.endocrine.org/intouch/) * [Member News](https://endocrinenews.endocrine.org/category/in-touch/member-news-in-touch/) * [Society News](https://endocrinenews.endocrine.org/category/in-touch/society-news/) * [Podcast](https://www.endocrine.org/podcast) * [Current Issue Download](https://endocrinenews.endocrine.org/magazine/current-issue/) * [My Profile](https://ams.endocrine.org/eweb/) * [Log In](https://endocrinenews.endocrine.org/auth/login) * [Log Out](https://endocrinenews.endocrine.org/auth/logout) Search Search [Current Issue Download](https://endocrinenews.endocrine.org/magazine-issues/november-2026/) [Login](https://endocrinenews.endocrine.org/auth/login/?redirect=https://endocrinenews.endocrine.org/pharma-friday-november-21-2026/) ![](https://endocrinenews.endocrine.org/wp-content/themes/mg-starter/assets/images/Endocrine_News_standard_logo.svg) * * * # Pharma Friday – November 21, 2026 November 20, 2026 Print this article Share this article ![](https://endocrinenews.endocrine.org/wp-content/uploads/pharmaaaaa.jpg) ##### An _Endocrine News_ roundup of the week’s pharmaceutical news, breakthroughs, and general information. * ## **Amylyx Pharmaceuticals Presents Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia** On November 14, [**Amylyx Pharmaceuticals, Inc.**](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.amylyx.com%2F&esheet=54640750&newsitemid=20261114240218&lan=en-US&anchor=Amylyx+Pharmaceuticals%2C+Inc.&index=1&md5=59af6ca1771b90b9171c72c351852121) presented the results from the 16-week double-blind treatment period of the Phase 3 LUCIDITY clinical trial of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist, in participants with post-bariatric hypoglycemia (PBH) following Roux-en-Y gastric bypass (RYGB) surgery. “The presentation of our Phase 3 LUCIDITY results represents a pivotal milestone in our work to address the longstanding treatment gap for people living with PBH. The results shared today reinforce the consistency and strength of the data, with avexitide demonstrating highly statistically significant and clinically meaningful reductions in hypoglycemic events across all prespecified endpoints,” said Endocrine Society member Camille L. Bedrosian, MD, chief medical officer at Amylyx. “These positive data, together with positive results from five prior trials of avexitide in PBH, support the potential for avexitide to change practice for this debilitating condition.” ![](https://endocrinenews.endocrine.org/wp-content/uploads/amylyx-logo.jpg) LUCIDITY met its prespecified primary endpoint, demonstrating a 55% reduction in the composite rate of self-monitoring of blood glucose (SMBG)-confirmed Level 2 and blinded Event Adjudication Committee (EAC)-adjudicated Level 3 hypoglycemic events compared with placebo (Least squares mean event rate of 0.55 events per week in avexitide arm compared to 1.24 events per week in placebo arm, p=0.0000034). LUCIDITY also met all prespecified, multiplicity-controlled secondary event-rate endpoints, reducing SMBG-confirmed Level 2 hypoglycemic events by 63% (p=0.0000032), EAC-adjudicated Level 3 hypoglycemic events by 47% (p=0.0016), and continuous glucose monitoring (CGM)-detected Level 2 hypoglycemic events by 42% (p=0.00016) compared with placebo. In a secondary analysis that evaluated change from baseline within each arm, events decreased by 72.9% in the avexitide arm and by 37.8% in the placebo arm (p=0.000034 for the between-arm difference). > “The debilitating nature of this condition is clear when you look at the participants of LUCIDITY. At baseline, the majority of participants entered the study experiencing daily hypoglycemia symptoms, with many reporting a history of loss of consciousness and hypoglycemia-related hospitalizations. This substantial disease burden makes the consistent reductions in hypoglycemic events seen with avexitide compelling.” > Endocrine Society member **Marilyn Tan, MD, FACP** , principal investigator of the LUCIDITY clinical trial and Clinical Professor at the Stanford School of Medicine Avexitide was generally well tolerated, with a safety profile consistent with that observed across prior PBH clinical trials. Treatment-emergent adverse events were primarily gastrointestinal and injection-site related and were generally mild to moderate in intensity. There were no deaths and no treatment-related serious adverse events. No clinically meaningful changes in body weight or fasting plasma glucose were observed during the 16-week double-blind treatment period. “PBH is a chronic metabolic condition characterized by recurrent hypoglycemia. Each hypoglycemic event carries the potential for serious acute consequences and the cumulative burden of living with recurrent and unpredictable events can significantly affect daily functioning, independence, health and quality of life,” said Endocrine Society member **Marilyn Tan, MD, FACP** , principal investigator of the LUCIDITY clinical trial and Clinical Professor at the Stanford School of Medicine. “The debilitating nature of this condition is clear when you look at the participants of LUCIDITY. At baseline, the majority of participants entered the study experiencing daily hypoglycemia symptoms, with many reporting a history of loss of consciousness and hypoglycemia-related hospitalizations. This substantial disease burden makes the consistent reductions in hypoglycemic events seen with avexitide compelling.” LUCIDITY is a multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial that enrolled 78 adults with PBH following RYBG surgery. After a 3-week run-in, participants were randomized 3:2 to avexitide 90mg subcutaneously once daily or placebo. Participants received standard-of-care dietary management for PBH throughout the run-in and 16-week double-blind treatment period. More than 90% of participants completed the double-blind treatment period, including 45/47 participants randomized to avexitide and 28/31 randomized to placebo. All eligible participants entered the 32-week open-label extension period. Baseline demographic and disease characteristics were generally balanced between groups. Participants in LUCIDITY had substantial disease burden at baseline: 68% reported daily hypoglycemic symptoms, 47% had a history of loss of consciousness, and 28% had a history of hypoglycemia-related hospitalizations. The FDA previously granted avexitide Breakthrough Therapy Designation for PBH. LUCIDITY’s 32-week open label extension period and the avexitide Expanded Access Program for eligible adults with PBH following RYGB surgery remain ongoing. ## FDA Clears MiniMed Fit™ — World’s First and Only Tubeless Insulin Pump with Up to Seven-Day Wear and Zero Interruptions On November 16, **[MiniMed](https://www.minimed.com/)** announced U.S. Food and Drug Administration (FDA) clearance of MiniMed Fit™, the company’s first tubeless insulin pump, offering people with diabetes a new differentiated option that combines up to seven days of wear, a 300-unit insulin capacity, app control and proven SmartGuard™ technology. MiniMed Fit™ marks a significant expansion of the company’s insulin delivery portfolio, bringing its advanced automated insulin delivery technology to a tubeless design for the first time. With up to twice the wear time of other tubeless options* and 50% more insulin capacity, the system reduces the number of pump changes and daily decisions, so there is less to do and less to think about with diabetes management. ![](https://endocrinenews.endocrine.org/wp-content/uploads/minimed-fit-straight-on-solo-1280x1280-1-1024x1024.jpg) _**The MiniMed Fit.**_ “People with diabetes shouldn’t have to choose between the freedom of tubeless wear and the health outcomes they deserve,” said Que Dallara, chief executive officer of MiniMed. “MiniMed Fit™ brings the technology people trust from MiniMed into a tubeless design that fits their lives. Clearing FDA ahead of schedule is more proof we’re executing our strategy. It puts MiniMed Fit in U.S. customers’ hands sooner, and the pharmacy channel makes it easier to get.” **Everything a tubeless pump should be** MiniMed Fit™ is designed to automate more of the work of diabetes management and reduce interruptions in daily routines. It combines a discreet, waterproof tubeless pump with app control on compatible iOS and Android devices and at commercial launch will offer the choice of two all-in-one sensors: Simplera Sync™ with up to seven days of wear and Instinct™, made by Abbott, with up to 15 days of wear. * **Fewer changes. More freedom.** With up to seven days of wear and 300-unit insulin capacity, MiniMed Fit™ offers up to twice the wear time and more insulin than other tubeless insulin pump options, meaning fewer pump changes and more time to focus on what matters. * **Automation every five minutes.** Powered by SmartGuard™ technology, the system automatically adjusts insulin delivery and can deliver correction doses every five minutes. * **Easier mealtimes.** With Meal Detection™ technology, the system can deliver additional insulin when a meal dose is sometimes missed or underestimated. * **More time in range, day and night.** Real-world users of SmartGuard™ technology have achieved up to 80% Time in Range and 91% overnight Time in Range with recommended settings, helping people spend more time in their target glucose range. * **Flexible wear locations and insulin compatibility.** Wear locations are back of arm, lower back, upper buttocks, abdomen, and thigh. Compatible insulins are Humalog, NovoLog, and Admelog. * **Easier access through the pharmacy.** MiniMed Fit™ will be available through the pharmacy channel, offering a convenient way for people to access. * **Built for what’s next.** MiniMed Fit™ is designed for future innovation, including the planned integration with MiniMed’s next-generation fully closed-loop technology (investigational). The MiniMed Fit™ launch is expected to begin with a phased rollout in the U.S. in spring 2027, following an early customer experience phase expected to begin in MiniMed’s fourth quarter of fiscal year 2027. ![](https://endocrinenews.endocrine.org/wp-content/uploads/minimed-fit-swimming-pool-champion-roman-torso-2048x2048-1-1024x683.jpg) **_Swimmer wearing the MinMed Fit._** In preparation for launch, MiniMed has been building manufacturing capacity and commercial infrastructure alongside the regulatory process. The company plans to significantly expand manufacturing capacity as commercialization progresses to support growing demand and capitalize on a new growth opportunity in tubeless insulin pumps. MiniMed Fit™ is cleared for people with Type 1 and Type 2 diabetes ages seven years and older. People interested in learning more about MiniMed Fit™ availability can request to receive updates at **[minimed.com/fit](https://www.minimed.com/en-us/products/minimed-fit-system?utm_source=pr&utm_medium=vanity)**. **About MiniMed** MiniMed is a global leader in insulin delivery, constantly advancing therapies that support people with diabetes in 80 countries. Our full-stack, integrated ecosystem, including our insulin delivery systems, CGMs, algorithms, and easy-to-use app experience, is designed to work seamlessly together, supported by white-glove, wrap-around service. For over 40 years, we’ve pioneered therapies people can rely on by anticipating needs, reducing burden, and helping make life with diabetes easier. Our mission is to make every day a better day for people with diabetes. ## PolarityBio Announces FDA Acceptance for Filing of SkinTE® BLA with Priority Review in Diabetic Foot Ulcers In September, [**PolarityBio**](https://www.polaritybio.com/)®, a late-stage biotechnology company addressing unmet needs in wound healing through innovation in regenerative multicellular biologics, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s Biologics License Application (BLA) for SkinTE® (autologous cutaneous multicellular units) for the treatment of Wagner Grade 1 diabetic foot ulcers (DFUs). The FDA has granted the application Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) target action date of March 16, 2027. Priority Review establishes an FDA goal of taking action on an application within six months, compared with 10 months under standard review. The FDA grants Priority Review to applications for products that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment of a serious condition. SkinTE previously received Regenerative Medicine Advanced Therapy (RMAT) and Breakthrough Therapy designations from the FDA for the treatment of Wagner Grade 1 DFUs. “FDA acceptance of our BLA and the grant of Priority Review reflect both the strength of the COVER DFUS II data package and the urgency of the need for patients living with chronic, non-healing diabetic foot ulcers,” said Nikolai Sopko, MD, PhD, president, chief operating officer, and chief scientific officer of PolarityBio. “Our focus now is on supporting an efficient review and on preparing to serve patients well if SkinTE is approved. We have built manufacturing, medical affairs and market access capabilities in parallel with the clinical program, and that work continues.” The BLA is supported by positive results from COVER DFUS II, PolarityBio’s pivotal Phase III randomized controlled trial evaluating SkinTE with standard of care compared with standard of care alone. The study met its primary efficacy endpoint
## Related Clinical Research

- [Later bedtimes and late eating tied to higher metabolic syndrome risk](https://medichelpline.com/clinical-feed/medical-news-today-0-eating-and-sleeping-later-associated-with-increased-health-risks.md)
- [Genomic SEM identifies shared genetic architecture and candidate genes for insulin resistance–rela](https://medichelpline.com/clinical-feed/plos-one-18-integrative-genomic-sem-analysis-of-shared-genetic-architecture-and-candidate.md)
- [Preconception, Gestational, and Postpartum Care for Type 2 Diabetes](https://medichelpline.com/clinical-feed/endocrine-news-0-preconception-gestational-and-postpartum-care.md)
- [Resistance exercise preserves lean mass during tirzepatide therapy for obesity](https://medichelpline.com/clinical-feed/nature-1-resistance-exercise-to-attenuate-lean-mass-loss-during-tirzepatide-therapy-for.md)
- [Endocrine Society Launches Diabetes SIG and Expands Education, Research, Advocacy](https://medichelpline.com/clinical-feed/endocrine-news-1-society-offers-full-spectrum-of-diabetes-resources-including-a-new-sig-for.md)

## Navigation
- [← Back to Endocrinology Feed](https://medichelpline.com/clinical-feed/endocrinology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.